Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN versus PIPERACILLIN AND TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN versus PIPERACILLIN AND TAZOBACTAM.
PIPERACILLIN vs PIPERACILLIN AND TAZOBACTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
3.375 g IV every 6 hours (piperacillin-tazobactam); for piperacillin alone, 3 g IV every 6 hours.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
None Documented
None Documented
0.6-1.2 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment (CrCl <20 mL/min); requires dose adjustment in renal failure
Clinical Note
moderatePiperacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Piperacillin."
Clinical Note
moderatePiperacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy."
Clinical Note
moderatePiperacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Piperacillin."
Clinical Note
moderatePiperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Renal: approximately 70-90% unchanged via glomerular filtration and tubular secretion; biliary: 10-20% excreted unchanged in bile; fecal: minor (<5%)
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Piperacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Piperacillin."